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Abstract
Objectives—In an entirely African-American cohort, we compared clinical characteristics,
cardiac structure and function, and all cause mortality in heart failure (HF) with preserved ejection
fraction (HFpEF) in relation to HF with reduced ejection fraction (HFrEF) and those without HF.
Background—African-Americans are at increased risk for HF. Nevertheless, there are limited
phenotypic and prognostic data in African-Americans with HFpEF compared to those with HFrEF
and those without HF.
Methods—Middle-aged African-Americans from the Jackson cohort of the Atherosclerosis Risk
in Communities study (n=2,445) underwent echocardiography between 1993 and 1995. HF
prevalence was available in 1,962 for whom left ventricular ejection fraction (LVEF) could be
quantified. Participants with HF were categorized as having HFpEF (LVEF ≥ 50%) or HFrEF
(LVEF < 50%), or no HF, with comparisons made between groups.
Results—HF was identified in 116 (5.9%) participants (n=85 [73%] HFpEF; n=31 [27%]
HFrEF). Compared to those without HF, those with HFpEF were older, more likely to be female,
had more frequent comorbidities, and concentric hypertrophy. In relation to HFrEF, those with
HFpEF were more likely female, but less likely to have coronary heart disease, diabetes mellitus,
chronic kidney disease, left atrial enlargement, and eccentric hypertrophy. Over a median 13.7
years of follow up, risk of death differed between groups, with age and sex adjusted hazard ratios
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of 1.51 (95%CI 1.01–2.25) for HFpEF vs. those without HF, and 2.50 (95%CI 1.37–4.58) for
HFrEF vs. HFpEF.
Conclusions—In this cohort of middle-aged African-Americans, HFpEF was the most common
form of HF, and was associated with a substantially better prognosis than HFrEF, but worse than
those without HF.
Keywords
African-Americans; heart failure with preserved ejection fraction; heart failure with reduced
ejection fraction; echocardiography; mortality
Introduction
African-Americans, as compared to other racial groups, are at increased risk for the
development of heart failure (HF) (1–3). Additionally, HF in African-Americans occurs at a
younger age and is associated with a higher prevalence of cardiovascular risk factors,
particularly hypertension and diabetes mellitus, but lower frequency of coronary heart
disease (CHD) (4–6). It has been suggested that the prevalence of HF and preserved ejection
fraction (HFpEF) may be higher in African-Americans than current estimates of HFpEF in
the general population (5,7,8). However, findings are mixed regarding survival in African-
Americans with HF (3,4,6,9) and information is limited concerning prognosis in African-
Americans with HFpEF (10,11). We therefore aimed to describe differences in clinical
characteristics, cardiac structure and function, and prognosis in a community based sample
of African-Americans with HFpEF as compared to those with HF and reduced ejection
fraction (HFrEF) and those without HF.
Methods
Study population
The Atherosclerosis Risk in Communities (ARIC) study is an ongoing, prospective
observational study of the natural history of atherosclerotic diseases and cardiovascular risk
factors. Detailed study rationale, design, and procedures have been previously published
(12). The original cohort was recruited between 1987–1989 using probability sampling of
middle aged (45–64 years old) men and women from 4 communities in the United States
(Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington County, MD). The
Jackson field center enrolled an entirely African American cohort. Subsequent follow up
visits occurred at 3 year intervals up to 1998, with annual telephone interviews conducted
between visits. Institutional review boards from each site approved the study and informed
consent was obtained from all participants.
Transthoracic echocardiography was only performed in the Jackson cohort during visit 3
(1993–1995). Of 2,445 participants who underwent transthoracic echocardiography, 1,962
were included in this analysis after sequential exclusion of 318 in whom left ventricular
ejection fraction (LVEF) could not be calculated, 32 with missing HF status, 3 in whom
incident HF occurred after visit 3 but before the echocardiogram, and 130 with missing
covariate data.
Echocardiography
Two-dimensional, M-mode, and Doppler images were acquired with an Acuson 128XP/10c
cardiac ultrasound machine with 2.5, 3.5, and 5.0 MHz transducers (Acuson, Malvern, PA).
Quality control measures have been previously described (13). Left ventricular (LV) end
diastolic diameter (LVEDD), LV end systolic diameter, septal and posterior wall thickness
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were measured from 2-dimensional images according to American Society of
Echocardiography criteria. LV mass was calculated using the simplified cubed equation and
indexed (LVMI) to height (meters2.7) with left ventricular hypertrophy (LVH) defined as an
LVMI ≥51g/m2.7 (14). Relative wall thickness was calculated as 2 × posterior wall
thickness/LVEDD with ≤ 0.42 considered normal. LVEF was calculated utilizing 2-D
Teichholz method, with a LVEF ≥ 50% and <50% defining preserved and reduced LVEF,
respectively. Diastolic dysfunction was determined based upon transmitral Doppler E to A
ratio, with ≤ 0.75 or > 1.5 considered abnormal (15).
Definition of Heart Failure
Prevalent HF at visit 3 was defined by a) stage 3 or manifest HF according to Gothenburg
criteria or the use of medications for HF at visit 1 (n=82) or b) hospitalization with ICD-9
code for HF (428.x) listed at discharge between visit 1 and 3 (n=34) (3). The Gothenburg
criterion is a validated scoring system composed of 3 components a) cardiac, b) pulmonary,
and c) therapy, in which stage 3 or manifest HF requires 1 point from each component (16).
Participants with quantifiable LVEF by echocardiography and prevalent HF were
categorized as HFpEF (LVEF ≥ 50%) or HFrEF (LVEF < 50%).
Covariates
Established definitions for hypertension, obesity, diabetes mellitus, CHD, stroke, smoking
status, and medication use as previously described in ARIC were utilized (17).
Electrocardiographic LVH was determined by Cornell criteria. Pulmonary disease was
defined as self reported history of physician diagnosed lung disease or asthma. Retinopathy,
estimated glomerular filtration rate, ankle brachial index, hematologic parameters, lipids,
and glucose were measured according to standardized protocols with chronic kidney disease
(CKD) and peripheral arterial disease defined as previously described (12,18–20). Ankle
brachial index was available in 1,239 participants. All covariates were ascertained at visit 3,
except for hemoglobin, white blood cell count, and creatinine, for which the most recent
prior measures were used.
Outcome
The primary outcome was death from any cause. The follow up period was defined as the
time elapsed from the date of echocardiography to the date of death, date of last contact for
those lost to follow-up, or December 31, 2008. Deaths were ascertained through annual
phone calls to participants and ongoing surveillance of health department certificate files.
Statistical Methods
For each of the 3 groups (non HF, HFpEF, and HFrEF), summary statistics for covariates
were calculated as counts and percentages, and medians and inter-quartile ranges for
categorical and continuous data, respectively. Comparisons were then made between a)
HFpEF and non-HF and b) HFpEF and HFrEF. Chi squared or Fisher’s exact test and
Wilcoxon rank-sum test were used to compare baseline characteristics. All cause mortality
rates were calculated (number of deaths divided by person-time at risk). Survival analysis
was performed according to the Kaplan Meier method with the log-rank test used to assess
for differences. Univariable and multivariable hazard ratios for death were estimated using
Cox proportional hazards regression. Covariates included in multivariable models included
age, gender, LVEF, and clinical characteristics. Propensity scores for HFpEF vs. non HF
and HFrEF vs. HFpEF were calculated using clinical characteristics that significantly
differed in univariate analyses between groups. The propensity score was then included in
Cox proportional hazards models. Two-sided p values <0.05 were considered significant.
Analyses were performed using Stata 11.2 (Stata Corp., College Station, Texas).
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Prevalent HF was identified in 116 (5.9%) participants and further classified as HFpEF
(n=85, 73%) and HFrEF (n=31, 27%). Those with HFpEF were older than those without HF,
but similar in age to those with HFrEF. Female sex was significantly more common in
HFpEF as compared to those without HF and HFrEF. There were no differences with regard
to heart rate or blood pressure. As expected, symptoms of HF, such as orthopnea,
paroxysmal nocturnal dyspnea, and lower extremity edema were more common among
those with HF as compared to those without HF (Table 1).
Comorbidities were common among those with HFpEF (Table 1). In particular,
hypertension, obesity, diabetes mellitus, pulmonary disease, peripheral arterial disease, and
CHD were more frequent among those with HFpEF as compared to those without HF. Of
note, hypertension was highly prevalent even in those without HF, approaching 60%.
Comorbidities were also common among those with HFrEF, with diabetes mellitus, CHD,
and CKD present more frequently than in HFpEF.
Cardiac structure and function differed between groups (Table 2). Those with HFpEF had
increased wall thickness and LVMI compared to those without HF, although prevalence of
diastolic dysfunction and left atrial enlargement did not differ between these two groups. In
contrast, those with HFrEF had the highest LV wall thickness and LVMI. Additionally, left
atrial enlargement and mitral regurgitation were more frequent among those with HFrEF as
compared to those with HFpEF. Concentric hypertrophy was the most common LV
geometry; however, it was significantly more frequent in HFpEF as compared to those
without HF. Hypertrophy was present in nearly all participants with HFrEF, with eccentric
hypertrophy more frequent in HFrEF as compared to HFpEF.
Over a median follow up of 13.7 years, deaths occurred in 21%, 31%, and 61% of those
without HF, with HFpEF, and with HFrEF, respectively (Table 3). Death rates in HFpEF
were increased compared to those without HF, but were lower than those with HFrEF, even
when adjusted for age. In age and gender adjusted Cox Proportional Hazards Models, risk of
death differed between groups. HFpEF was associated with a 51% increased risk of death as
compared to those without HF (HR 1.51, 95%CI 1.01–2.25). HFrEF was associated with the
worst survival, with 2.5 times the risk of death as compared to those with HFpEF (HR 2.50,
95%CI 1.37–4.58). When further adjusted for LVEF, HFpEF was associated with 61%
increased risk of death as compared to those without HF (HR 1.61, 95%CI 1.08–2.41).
Adjustment for differences in clinical characteristics attenuated the mortality risk associated
with HFpEF vs. those without HF; however, those with HFrEF remained at significantly
increased risk of death compared to those with HFpEF (Table 3, Figure 1).
Discussion
In a community based sample of middle-aged African-Americans, we found that
demographic and clinical characteristics as well as cardiac structure and function
significantly differed between HFpEF, HFrEF, and those without HF. By comparing HFpEF
to those without HF, we found that older age, female sex, hypertension, obesity, diabetes
mellitus, and concentric hypertrophy were more common in HFpEF. Similarly, diabetes
mellitus, CKD, CHD, and left atrial enlargement were more common in HFrEF than HFpEF.
Survival differed between groups, with HFpEF portending a worse prognosis than those
without HF, but not as severe as HFrEF. Together, these findings suggest that in African-
Americans HFpEF and HFrEF may be distinct syndromes.
Representation of African-Americans in observational studies and clinical trials is typically
low, thus HF in this population is not well understood (21,22). Moreover, few HF studies
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focus specifically on African-Americans (23), as most literature involving race in HF
addresses differences between racial groups. This is in spite of a higher prevalence of
cardiovascular risk factors and greater burden of HF among African-Americans. The
existing literature suggests the development and progression of HF in African Americans
may be characterized by predominantly non-ischemic etiologies, more severe natural
history, and possibly a different response to pharmacotherapy when compared to
predominantly Caucasian studies (9,21). By evaluating an entirely African-American cohort,
our findings may advance understanding of HF in this high risk population.
Approximately three quarters of African-Americans with HF in our cohort had HFpEF. This
is concordant with two population based studies of ambulatory HF patients, where 57–76%
had preserved systolic function (7,24), but differs from an ambulatory Veterans
Administration population where HFpEF was present in 25% (25). However, only 6% of
those in the Veterans Administration study were female, and therefore may not be
representative of the typical HFpEF population (25). In comparison, 65% of the Jackson
cohort was female, which may be one explanation for the higher prevalence of HFpEF. Our
findings are also consistent with population studies of ambulatory HF patients that included
multiple ethnicities and demonstrated a higher prevalence of HFpEF than HFrEF (26–28).
However, our results contrast with studies evaluating African-Americans hospitalized with
acute decompensated HF where HFpEF was prevalent in 29–43% (5,6,29), suggesting the
relative frequency of HFpEF and HFrEF may differ between hospitalized and ambulatory
settings (30). Additionally, the finding that HFpEF was more common than HFrEF may be
explained, in part, by the high prevalence of hypertension and relatively low frequency of
CHD.
Regardless of preserved or reduced LVEF, comorbidities were common in HF. However,
the pattern of clinical characteristics differed between HFpEF and HFrEF. In addition to
diabetes mellitus and CKD, CHD was more frequent in HFrEF as compared to HFpEF,
although it was only present in one third of those with HFrEF despite the high prevalence of
atherosclerotic risk factors. Overall, CHD was not as common in HF as typically described
in predominantly white populations, which may be partially explained by the relatively high
proportion of women and middle age range in this study. Hypertension, however, was
present in 85% of those with HF. Together, these findings suggest that hypertension, along
with other comorbidities, such as obesity, diabetes mellitus, and CKD, rather than CHD,
may be relatively more important factors in HF in African-Americans.
The most striking finding related to cardiac structure was the marked prevalence of LVH not
only in those with HF, but also among those without HF. While hypertension may be the
most common contributor to hypertrophy, other factors including obesity (31,32), diabetes
mellitus (33,34), the metabolic syndrome (35), and CKD (36), have previously been
demonstrated to be associated with LVH. Several studies have shown that these
comorbidities are common in HF particularly among African-Americans and Hispanics
(4,37). In our analysis, these comorbidities were frequent in HF, and a particularly
worrisome finding was that concentric hypertrophy was present in 60% of those without HF.
The high prevalence of hypertension and concentric LVH, a known marker of increased
cardiovascular risk in African-Americans (38), portends a potential increase in HF among
this group (39).
There is also uncertainty regarding the risk of death in chronic HF among African-
Americans (5). Registries of hospitalized HF patients suggest similar or better survival in
African-Americans vs. whites (4–6,40). This is congruent with previous reports from ARIC
demonstrating similar mortality rates between races at 30 days and 1 year; however, the
longer follow up time in ARIC revealed higher fatality rates in African-Americans at 5 years
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post HF hospitalization (3). Few studies have evaluated survival in HFpEF in African-
Americans. In a predominantly male Veterans Administration population, survival over 5
years of follow up did not differ according to race among those with HFpEF, although
among African-Americans HFpEF appeared to be associated with a similar or slightly better
prognosis than HFrEF (10). Results from the Duke Databank of Cardiovascular Disease
suggest a better 5 year survival in HFpEF (68%) (11), as compared to HFrEF (51%) (41),
although a direct comparison of mortality between HFpEF and HFrEF in African-Americans
was not made.
We found that HFpEF was associated with a more benign prognosis than HFrEF. This is
consistent a meta-analysis of nearly 42,000 patients with HF that demonstrated a 32% lower
risk of death in HFpEF as compared to HFrEF, although stratification according to race was
not reported (42). It is also consistent with the Candesartan in Heart failure Assessment of
Reduction in Mortality and morbidity (CHARM) trial (43), but differs from epidemiologic
data from Olmsted County, Enhanced Feedback for Effective Cardiac Treatment, and the
Framingham Heart Study where mortality rates were similar between HFpEF and HFrEF
(44–46). This may, in part, be explained by differences in study populations, as those that
capture patients during or immediately following an acute hospitalization find that HFpEF
and HFrEF have similar mortality, particularly among the elderly (30). In contrast,
ambulatory HF patients, such as those in the Cardiovascular Health and Strong Heart
studies, which enrolled an older biracial population and Native Americans, respectively,
demonstrate lower fatality rates in HFpEF vs. HFrEF (26,27). However, representation of
African-Americans in these studies was generally low, limiting applicability to this race.
We also found the mortality rate in HFpEF to be greater than that of those without HF. The
risk of death in HFpEF was 61% higher than age, gender, and LVEF matched participants
without prevalent HF. However, adjustment for additional clinical characteristics attenuated
this risk. It has been proposed that HFpEF is a collection of comorbidities and that the
syndrome of HFpEF may not even exist (47). In contrast, pooled analyses of clinical trials of
HFpEF and cardiovascular trials of patients without HF demonstrate higher mortality rates
in HFpEF as compared to those without HF (48). Our data in African-Americans are
consistent with these pooled analyses. Although adjustment for comorbidities attenuated this
risk, the relatively small numbers of deaths in our HFpEF population limited our statistical
power. Nevertheless, our findings highlight the importance of comorbidities in African
Americans with HFpEF, but do not mitigate the broader literature demonstrating that HFpEF
is associated with a worse prognosis than those without HF.
Recent literature also suggests that half of all deaths in HFpEF may not be related to
cardiovascular causes (49–51), again emphasizing the impact of comorbidities (37,52). We
extend these findings by showing that non-cardiovascular comorbidities are frequent among
African-Americans with HF. Furthermore, using ICD codes (recognizing their limitation in
identifying cause of death), we observed a similar trend to previous reports; namely that
58%, 44% and 26% of deaths in those without HF, with HFpEF, and HFrEF, respectively,
were due to non-cardiovascular causes (Figure 2). Together these findings emphasize the
importance of treating comorbidities, particularly among those with HFpEF, as a potential
approach to improving outcomes (37,49,52,53).
While we specifically evaluated an entirely African-American cohort over a long follow up
period, limitations should be noted. The cross sectional design precludes assessment of
causality between clinical characteristics, cardiac structure and function, and HF. However,
differences between HFpEF, HFrEF, and those without HF may provide insight into targets
for future investigation. The definition for prevalent HF was based upon Gothenburg criteria
and unadjudicated hospitalization ICD-9 codes, although these methods have been validated
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in ARIC (3,54). Importantly, this approach captures participants with prior or current
symptoms of HF, as recommended by ACC/AHA staging of HF (55). LVEF was not
assessed at the time of incident HF and it is possible that LVEF may have recovered
between the incident HF event and our assessment. However, LVEF has previously been
demonstrated to be similar between acute and chronic HF (56). Moreover, our findings
suggest LVEF measured after incident HF still imparts prognostic information. Teichholz’
method was used to calculate LVEF as volumetric measurements were not available.
Diastolic function was assessed with transmitral Doppler E/A ratio as estimation of left atrial
volumes, tissue Doppler imaging, transmitral E wave deceleration time, pulmonary venous
flow, and isovolumic relaxation time were not obtained at echocardiography. While diastolic
dysfunction is frequently reported in HFpEF, we found it to be present in 25% of
participants with HFpEF, which did not differ between HFpEF and those without HF, likely
reflecting limitations in diastolic assessment. There may have been selection bias with
regard to participants who presented for echocardiography or had interpretable images, such
that the sickest individuals, including more severe HF, may be underrepresented. Inherent to
ARIC’s design, this study includes a selected age range and consisted entirely of African-
Americans from Jackson. Therefore, our results may not be generalizable to younger, more
elderly, or all African-Americans. However, the mean age of African-Americans in most HF
registries was 63–64 years old, falling within the range of our cohort (4–6,25). The observed
mortality rates may not be directly applicable to a more contemporary time period due to
temporal changes in HF management. Finally, the relatively low numbers of participants
with prevalent HF may limit statistical power.
In summary, we found in a community based sample of middle-aged African-Americans,
that demographic and clinical characteristics, as well as cardiac structure and function,
significantly differed between HFpEF, HFrEF, and those without HF. HFpEF was more
common than HFrEF and portended a worse prognosis than those without HF, but not as
severe as HFrEF. As this population bears a disproportionate burden of HF, focused
investigation on African-Americans is an important step to understanding HF and
developing strategies for prevention, detection, and treatment.
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HFpEF heart failure with preserved ejection fraction
HFrEF heart failure with reduced ejection fraction
ARIC Atherosclerosis Risk in Communities
LV Left ventricular
LVEF Left ventricular ejection fraction
LVEDD Left ventricular end diastolic diameter
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LVMI Left ventricular mass index
CHD Coronary heart disease
CKD Chronic kidney disease
LVH Left ventricular hypertrophy
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Figure 1. Survival in African-Americans according to heart failure status
Kaplan-Meier survival analysis in those without heart failure (nonHF), heart failure with
preserved ejection fraction (HFpEF), and those with heart failure and reduced ejection
fraction (HFrEF).
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Figure 2. Proportion of deaths due to cardiovascular and non-cardiovascular causes according to
heart failure status in African-Americans
Cause of death ascertained from ICD-9 codes. HFpEF = heart failure with preserved ejection
fraction, HFrEF = heart failure with reduced ejection fraction, nonHF = no heart failure.
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Table 3








Deaths and mortality rates
  Deaths, n (%) 393 (21) 26 (31) 19 (61)
  Person-Time (yrs) 23,707 1,032 291
  Deaths / 100 person yrs* (95% CI) 1.66 (1.50,1.83) 2.52 (1.72,3.70) 6.52 (4.16,10.22)




  Unadjusted 1.55 (1.04,2.30) 2.62 (1.45,4.75)
  Age, gender adjusted 1.51 (1.01,2.25) 2.50 (1.37,4.58)
  Age, gender, LVEF† adjusted 1.61 (1.08–2.41) n/a
  Age, gender, LVEF†, Propensity score‡ adjusted 1.35 (0.87–2.09) 2.29 (1.19–4.42)
*
Death rates standardized to median age (58.7 years) of cohort.
†
LVEF not included in comparison of HFrEF vs. HFpEF
‡
Propensity score calculated utilizing baseline characteristics that significantly differed between groups.
LVEF = Left ventricular ejection fraction
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